機構股票研究
機構股票研究
機構股票研究
機構股票研究 
 
Page | 1 | PHILLISECURITIES (HK) RESEARCH 
華東醫藥
華東醫藥
華東醫藥
華東醫藥 (000963.CH) 
動力強勁，估值吸引 
 
中國
中國
中國
中國 | 醫藥
醫藥
醫藥
醫藥| 公司研報
公司研報
公司研報
公司研報 
 
 
 
20 April 2017 
 
 
投資總結
投資總結
投資總結
投資總結 
 
新版醫保目錄及藥品招標預期將令公司主要品種維持強勁增長，新進入品種亦有
望較快放量，再加上不斷完善的產品梯隊，料將支撐公司中長期發展。同時，主要股
東巨額認購定增項目，亦彰顯其對公司發展信心。我們給予其對應2017 年每股收益
30 倍估值，目標價為113 元，首予“買入”評級。(現價截至4 月18 日) 
 
Historical P/E Valuation 
 
Source: Bloomberg, Phillip Securities (HK) Research 
 
Peer Comparison 
Ticker
Company
MV(CNY:mn)
PE-TTM
PE-2017F
PE-2018F
PB
601607.SH
Shanghai Pharmaceutical
59,237
--
17.47
15.27
2.02
600998.SH
Jointown Pharmaceutical
33,006
--
29.41
23.11
3.03
600056.SH
China Meheco
25,644
--
21.49
17.49
3.73
600196.SH
Fosun Pharmaceutical
129,016
25.93
21.94
18.85
3.29
600276.SH
Hengrui Medicine
70,760
49.83
40.65
33.35
10.41
600867.SH
Tonghua Dongbao
30,316
47.30
36.68
28.74
7.70
600535.SH
Tasly
43,446
35.68
28.32
24.04
5.25
Average
39.69
27.99
22.98
5.06
000963.SZ
Huadong Medicine
45,213
31.01
24.72
20.18
6.21 
Source: WIND, Phillip Securities (HK) Research 
 
2016
2016
2016
2016 年業績超預期
年業績超預期
年業績超預期
年業績超預期 
 
華東醫藥2016 年實現營收253.8 億元，同比增長16.8%，歸屬于上市公司股東的
扣非淨利潤14.1 億元，同比增長32.5%，總體超預期。而且，公司擬向全體股東每10
股派發現金股利13.5 元（含稅），同時以資本公積金每10 股轉增股本10 股。這是公
司近十年來首次送股，將提升流動性。 
 
 
 
買入
買入
買入
買入 (首次
首次
首次
首次) 
現價: CNY 93.03 
(現價截至4 月18 日) 
目標價: CNY 113.00 (+21.4%) 
 
公司資料
公司資料
公司資料
公司資料 
普通股股東 (百萬股) : 
486
市值 (人民幣百萬元) : 
45,213
52 周 最高價/最低價 (人民幣元) :
94.65/ 59.82
 
 
 
 
主要股東
主要股東
主要股東
主要股東， % 
中國遠大集團: 
41.77
 
 
 
股價表現
股價表現
股價表現
股價表現， % 
1 個月
個月
個月
個月
3 個月
個月
個月
個月
1 年
華東醫藥 
10.29
23.45
27.14
滬深300 
10.76
19.80
22.46
 
股價
股價
股價
股價 & 滬深
滬深
滬深
滬深300 
 
Source: Phillip Securities (HK) Research 
 
財務資料
財務資料
財務資料
財務資料 
CNY mn 
FY14
FY15
FY16E
FY17E
Net Sales 
21623 25248 29856 34705
Net Profit 
1097
1447
1829
2241
EPS, CNY 
2.53
3.00
3.76
4.61
PER, x 
36.77
31.01
24.72
20.18
BVPS, CNY 
6.84
14.97
18.14
20.95
P/BV, x 
13.59
6.21
5.13
4.44
ROE, %  
41.88
28.23
22.23
23.59
Debt/Equity (%)
252.0
89.2
81.8
81.8
Source: Company reports, Phillip Securities Est. 
 
研研研研研 
笵國和
國和
國和
國和  
(+ 86 21 51699400-110) 
fanguohe@phillip.com.cn 
 
 
 
 
Page | 2 | PHILLISECURITIES (HK) RESEARCH 
華東醫藥
華東醫藥
華東醫藥
華東醫藥（000963 CH）公司研報
公司研報
公司研報
公司研報 
 
具體而言，醫藥工業業務營收58.5 億元，同比增長17.8%，毛率80.5%，
維持快速增長趨勢。公司核心品種百令膠囊收入突破20 億元，增速逾20%，阿
卡波糖則超過15 億元，增幅近30%，免疫抑制劑三個主要品種環孢素、嗎替麥
考酚酯、他克莫司合計營收約10 億元。 
 
商業業務實現營收201 億元，同比增長16.4%，毛利率7.9%，維持在8%左
右，主要得益於浙江省醫藥商業行業集中度提升。還值一提的是，公司正從傳
統流通商轉向綜合健康服務供應商，子公司寧波公司在醫美和大健康領域精耕
細作，代理進口美容產品伊婉連續三年保持翻番式增長，2016 年銷售突破4 億
元，淨利潤提至1.49 億元，同比增長62.53%。 
 
Pharmaceutical Commerce Business (RMB: mn) 
 
Source: Company reports, Phillip Securities (HK) Research 
 
費用方面，2016 年財務費用0.9 億元，同比下降1.2 億元，因公司定增
34.7 億元明顯改善財務狀況，這也是業績增速明顯快于營收增速的主要因素。 
 
醫保目錄調整助力快速成長
醫保目錄調整助力快速成長
醫保目錄調整助力快速成長
醫保目錄調整助力快速成長 
 
根據2017 版醫保目錄，公司3 個藥品新納入，阿卡波糖片由乙類調整為甲
類，另有他克莫司膠囊等3 個產品取消了適用症，因此，公司成為新版目錄主
要受惠者之一。 
 
百令從腫瘤輔助用藥改為氣血雙補劑，利好未來進行多科室拓展。而且，
百令膠囊市場目前主要以城區公立醫院為主，未來分級診療推進將帶動整體市
場擴大。同時，江東年產1200 噸發酵冬蟲夏草菌粉專案（一期專案）順利通過
GMP 現場核查，有效解決產能瓶頸問題。我們預期百令有望維持20%以上增速。 
 
阿卡波糖由乙類升級為甲類，終端支付能力提升有望形成放量效應。目前
阿卡波糖市場主要以原研廠商拜耳為主，但華東醫藥及綠葉產品具備價格優
勢，不僅在招標中有競爭力，在基層覆蓋率也超過原研藥，未來進口替代效應
將進一步提升，總體預計維持30%以上增速。 
 
 
 
 
 
 
 
 
Page | 3 | PHILLISECURITIES (HK) RESEARCH 
華東醫藥
華東醫藥
華東醫藥
華東醫藥（000963 CH）公司研報
公司研報
公司研報
公司研報 
Bidding price of Acarbose (CNY) 
 
Source: Company reports, Phillip Securities (HK) Research 
 
此外，達托黴素、吲哚布芬等首仿或獨家品種進入醫保，未來亦將隨著招
標推進進一步放量。目前，達托黴素已在上海中標。而且，新版目錄取消了他
克莫司口服製劑和環孢素的適應症限制，還將有利於其進行多科室推廣。 
 
產品儲備豐富
產品儲備豐富
產品儲備豐富
產品儲備豐富 
     
目前，除了強化腎病、內分泌、免疫抑制、消化系統等專科領域外，公司
還努力拓展抗腫瘤、抗重症感染與心血管等新領域。2016 年公司共取得甲磺酸
伊馬替尼片、利奈唑胺片等13 個臨床批件，獲得了百令顆粒劑、吲哚布芬片、
地西他濱原料及製劑4 個生產批件。此外，泮立蘇粉針方面，公司還是國內首
家向美國FDA 遞交ANDA 申請並受理，並啟動了他克莫司膠囊在海外的臨床研
究。因此，公司在藥品製劑的產品梯隊還將為未來發展提供動力。 
 
風險
風險
風險
風險 
 
主要產品降價超預期； 
產品推廣不及預期； 
“兩票制”落地低於預期。 
 
 
 
 
 
 
 
 
 
 
 
Page | 4 | PHILLISECURITIES (HK) RESEARCH 
華東醫藥
華東醫藥
華東醫藥
華東醫藥（000963 CH）公司研報
公司研報
公司研報
公司研報 
 
財務報告
財務報告
財務報告
財務報告 
 
Periodicity:
Periodicity:
Periodicity:
Periodicity:
2014
2014
2014
2014
2015
2015
2015
2015
2016
2016
2016
2016
2017F
2017F
2017F
2017F
2018F
2018F
2018F
2018F
Price Earnings
53.47
36.77
31.01
24.72
20.18
Price to Book
17.81
13.59
6.21
5.13
4.44
Dividend Yield
0.99%
1.34%
1.45%
1.93%
2.26%
EPS Adjusted
1.74
2.53
3.00
3.76
4.61
Book Value Per Share
5.22
6.84
14.97
18.14
20.95
Dividends Per Share
0.92
1.25
1.35
1.80
2.10
Revenue growth
-
14.65%
16.76%
18.25%
16.24%
Gross profit growth
-
25.20%
18.09%
20.34%
15.70%
Net profit growth
-
44.97%
31.88%
26.47%
17.92%
Gross Margin
21.62%
23.61%
23.88%
24.30%
24.65%
Operating Margin
6.91%
7.31%
7.62%
8.07%
8.45%
Net Profit Margin
4.01%
5.07%
5.73%
6.13%
6.46%
Dividend Payout Ratio %
52.87%
49.41%
45.00%
47.82%
45.55%
Return on Assets
9.07%
10.74%
11.18%
12.00%
12.98%
Return on Equity
31.27%
41.88%
28.23%
22.23%
23.59%
Liability ratio
72.04%
71.59%
47.14%
45.00%
45.00%
Effective Tax Rate
19.62%
18.86%
18.43%
18.50%
18.50%
Revenue
Revenue
Revenue
Revenue
18,860
18,860
18,860
18,860
21,623
21,623
21,623
21,623
25,248
25,248
25,248
25,248
29,856
29,856
29,856
29,856
34,705
34,705
34,705
34,705
     - Cost of Goods Sold
14,783
16,518
19,219
22,601
26,151
Gross Income
Gross Income
Gross Income
Gross Income
4,078
4,078
4,078
4,078
5,105
5,105
5,105
5,105
6,029
6,029
6,029
6,029
7,255
7,255
7,255
7,255
8,555
8,555
8,555
8,555
     - Selling, General & Admin Expenses
2,774
3,525
4,105
4,846
5,622
Operating Income
Operating Income
Operating Income
Operating Income
1,304
1,304
1,304
1,304
1,580
1,580
1,580
1,580
1,924
1,924
1,924
1,924
2,409
2,409
2,409
2,409
2,933
2,933
2,933
2,933
     - Interest Expense
150
172
78
75
80
     - Net Non-Operating Losses (Gains)
-20
-24
-50
-45
-50
Pretax Income
1,173
1,420
1,882
2,374
2,898
     - Income Tax Expense
230
268
347
439
536
Income Before XO Items
943
1,152
1,535
1,935
2,362
     - Minority Interests
186
55
89
106
120
Net Profit
Net Profit
Net Profit
Net Profit
757
757
757
757
1,097
1,097
1,097
1,097
1,447
1,447
1,447
1,447
1,829
1,829
1,829
1,829
2,241
2,241
2,241
2,241
Valuation Ratios
Valuation Ratios
Valuation Ratios
Valuation Ratios
Per share data(CNY)
Per share data(CNY)
Per share data(CNY)
Per share data(CNY)
Growth & Margin
Growth & Margin
Growth & Margin
Growth & Margin
Key ratios
Key ratios
Key ratios
Key ratios
Income Statement(CNY: mn)
Income Statement(CNY: mn)
Income Statement(CNY: mn)
Income Statement(CNY: mn)
Source: Company, Phillip Securities (HK) Research Estimates 
(財務資料截至4 月18 日) 
  
 
 
 
 
 
 
 
 
 
 
 
 
PHILL
 
華東醫藥
華東醫藥
華東醫藥
華東醫藥（000963 CH）公司研報
公司研報
公司研報
公司研報 
PHILLIP RESEARCH STOCK SELECTION SYSTEMS 
 
We do not base our recommendations entirely on the above quantitative return bands.  We consider qualitative factors like (but not limited to) a 
stock's risk reward profile, market sentiment, recent rate of share price appreciation, presence or absence of stock price catalysts, and speculative 
undertones surrounding the stock, before making our final recommendation 
 
GENERAL DISCLAIMER 
This publication is prepared by Phillip Securities (Hong Kong) Ltd (“Phillip Securities”). By receiving or reading this publication, you agree to be bound by the terms and 
limitations set out below. 
 
This publication shall not be reproduced in whole or in part, distributed or published by you for any purpose. Phillip Securities shall not be liable for any direct or 
consequential loss arising from any use of material contained in this publication. 
 
The information contained in this publication has been obtained from public sources which Phillip Securities has no reason to believe are unreliable and any analysis, 
forecasts, projections, expectations and opinions (collectively the “Research”) contained in this publication are based on such information and are expressions of belief 
only. Phillip Securities has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, 
complete or verified or should be relied upon as such. Any such information or Research contained in this publication is subject to change, and Phillip Securities shall not 
have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will 
Phillip Securities be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made 
available, even if it has been advised of the possibility of such damages. 
 
Any opinions, forecasts, assumptions, estimates, valuations and prices contained in this material are as of the date indicated and are subject to change at any time 
without prior notice. 
 
This material is intended for general circulation only and does not take into account the specific investment objectives, financial situation or particular needs of any 
particular person. The products mentioned in this material may not be suitable for all investors and a person receiving or reading this material should seek advice from a 
financial adviser regarding the suitability of such products, taking into account the specific investment objectives, financial situation or particular needs of that person, 
before making a commitment to invest in any of such products. 
This publication should not be relied upon as authoritative without further being subject to the recipient’s own independent verification and exercise of judgment. The 
fact that this publication has been made available constitutes neither a recommendation to enter into a particular transaction nor a representation that any product 
described in this material is suitable or appropriate for the recipient. Recipients should be aware that many of the products which may be described in this publication 
involve significant risks and may not be suitable for all investors, and that any decision to enter into transactions involving such products should not be made unless all 
such risks are understood and an independent determination has been made that such transactions would be appropriate. Any discussion of the risks contained herein 
with respect to any product should not be considered to be a disclosure of all risks or a complete discussion of such risks. 
 
Nothing in this report shall be construed to be an offer or solicitation for the purchase or sale of a security. Any decision to purchase securities mentioned in this research 
should take into account existing public information, including any registered prospectus in respect of such security. 
 
Disclosure of Interest 
Analyst Disclosure: Neither the analyst(s) preparing this report nor his associate has any financial interest in or serves as an officer of the listed corporation covered in 
this report. 
Firm’s Disclosure: Phillip Securities does not have any investment banking relationship with the listed corporation covered in this report nor any financial interest of 1% or 
more of the market capitalization in the listed corporation. In addition, no executive staff of Phillip Securities serves as an officer of the listed corporation. 
 
Availability 
The information, tools and material presented herein are not directed, intended for distribution to or use by, any person or entity in any jurisdiction or country where 
such distribution, publication, availability or use would be contrary to the applicable law or regulation or which would subject Phillip Securities to any registration or 
licensing or other requirement, or penalty for contravention of such requirements within such jurisdiction. 
 
Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited (“PSHK”) believed to be accurate. PSHK does not bear responsibility for any 
loss occasioned by reliance placed upon the contents hereof.  PSHK (or its affiliates or employees) may have positions in relevant investment products. For details of 
different product's risks, please visit the Risk Disclosures Statement on http://www.phillip.com.hk.   
© 
2017 Phillip Securities (Hong Kong) Limited 
 
Contact Information (Regional Member Companies) 
Total Return 
Recommendation 
Rating 
Remarks 
>+20% 
Buy 
1 
>20% upside from the current price 
+5% to +20% 
Accumulate 
2 
+5% to +20%upside from the current price 
-5% to +5% 
Neutral 
3 
Trade within  ± 5% from the current price 
-5% to -20% 
Reduce 
4 
-5% to -20% downside from the current price 
<-20% 
Sell 
5 
>20%downside from the current price 
 
 
 
PHILL
 
華東醫藥
華東醫藥
華東醫藥
華東醫藥（000963 CH）公司研報
公司研報
公司研報
公司研報 
SINGAPORE 
Phillip Securities Pte Ltd 
Raffles City Tower 
250, North Bridge Road #06-00 
Singapore 179101 
Tel : (65) 6533 6001 
Fax : (65) 6535 6631 
Website: www.poems.com.sg 
MALAYSIA 
Phillip Capital Management Sdn Bhd 
B-3-6 Block B Level 3 Megan Avenue II, 
No. 12, Jalan Yap Kwan Seng, 50450 
Kuala Lumpur 
Tel (603) 21628841 
Fax (603) 21665099 
Website: www.poems.com.my 
 
HONG KONG 
Phillip Securities (HK) Ltd 
Exchange Participant of the Stock Exchange of Hong Kong 
11/F United Centre 95 Queensway 
Hong Kong 
Tel (852) 22776600 
Fax (852) 28685307 
Websites: www.phillip.com.hk 
 
JAPAN 
PhillipCapital Japan K.K. 
Nagata-cho Bldg., 
8F, 2-4-3 Nagata-cho, 
Chiyoda-ku, Tokyo 100-0014 
Tel (81-3) 35953631 
Fax (81-3) 35953630 
Website:www.phillip.co.jp 
 
INDONESIA 
PT Phillip Securities Indonesia 
ANZ Tower Level 23B, 
Jl Jend Sudirman Kav 33A 
Jakarta 10220 – Indonesia 
Tel (62-21) 57900800 
Fax (62-21) 57900809 
Website:www.phillip.co.id 
 
CHINA 
Phillip Financial Advisory (Shanghai) Co. Ltd 
No 436 Hengfeng Road, 
Greentech Unit 604, 
Postal code 200070 
Tel (86-21) 51699400 
Fax (86-21) 63532643 
Website: www.phillip.com.cn 
 
THAILAND 
Phillip Securities (Thailand) Public Co. Ltd 
15th Floor, Vorawat Building, 
849 Silom Road, Silom, Bangrak, 
Bangkok 10500 Thailand 
Tel (66-2) 6351700 / 22680999 
Fax (66-2) 22680921 
Websitewww.phillip.co.th 
 
FRANCE 
King & Shaxson Capital Limited 
3rd Floor, 35 Rue de la Bienfaisance 75008 
Paris France 
Tel (33-1) 45633100 
Fax (33-1) 45636017 
Website: www.kingandshaxson.com 
 
UNITED KINGDOM 
King & Shaxson Capital Limited 
6th Floor, Candlewick House, 
120 Cannon Street, 
London, EC4N 6AS 
Tel (44-20) 7426 5950 
Fax (44-20) 7626 1757 
Website: www.kingandshaxson.com 
 
UNITED STATES 
Phillip Futures Inc 
141 W Jackson Blvd Ste 3050 
The Chicago Board of Trade Building 
Chicago, IL 60604 USA 
Tel +1.312.356.9000 
Fax +1.312.356.9005 
 
AUSTRALIA 
PhillipCapital Australia 
Level 12, 15 William Street, 
Melbourne, Victoria 3000, Australia 
Tel (613) 96188238 
Fax (613) 92002272 
Website: www.phillipcapital.com.au 
 
 
